Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
In the absence of other risk factors, do you treat the regional lymph nodes in triple negative breast cancer?
Or for that matter, offer PMRT on the basis of a patient having triple negative disease?
Answer from: Radiation Oncologist at Community Practice
At present I don't, but once Canadian and EORTC studies are published with full details available, it may change practice patterns.
Sign In
or
Register
to read more
415
Related Questions
Is it appropriate to use bolus with hypofractionated PMRT?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
For a patient who previously underwent PBI and then developed a second ipsilateral primary, would you offer repeat PBI?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
How do you treat a patient with early-stage breast cancer s/p lumpectomy and oncoplastic reconstruction with a positive margin, when re-excision is not feasible?
Would you recommend post mastectomy radiation for a low grade adenoid cystic carcinoma of the breast resected with negative margins?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?